Related Experiment Video
Updated: Jan 17, 2026
10:07
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
15.6K
Characterization of Next-Generation Inhibitors for the Inward-Rectifier Potassium Channel Kir2.1: Discovery of
Renn A Duncan1,2, Daniel H Haymer1,2, Roman M Lazarenko3
1Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
ACS Medicinal Chemistry Letters
|September 17, 2025
Summary
Researchers developed improved inhibitors for the inward-rectifier potassium channel Kir2.1, addressing the limitations of the existing tool compound ML133. The new compounds show enhanced potency and suitable pharmacokinetic properties for rodent studies.
Area of Science:
- Pharmacology
- Molecular Biology
- Cardiovascular Research
Background:
- ML133 is a widely used selective inhibitor of the inward-rectifier potassium channel Kir2.1.
- ML133 exhibits modest potency (IC50 = 1.5 μM) and its in vivo pharmacokinetics were previously unknown.
Purpose of the Study:
- To develop a next-generation series of Kir2.1 inhibitors based on the ML133 scaffold.
- To characterize the in vivo pharmacokinetics of ML133 and novel analogs in rats.
- To identify an improved Kir2.1 tool compound with superior potency and favorable pharmacokinetic properties.
Main Methods:
- Medicinal chemistry to design and synthesize novel Kir2.1 inhibitors.
- Functional assays including manual patch clamp (MPC) and thallium flux assays to assess potency.
- Pharmacokinetic studies in rats to evaluate drug behavior in vivo.
Main Results:
- A new series of Kir2.1 inhibitors based on the ML133 scaffold was successfully synthesized.
- Compound 5s (VU6080824) demonstrated superior potency compared to ML133 in both thallium flux and MPC assays.
- Compound 5s exhibited excellent pharmacokinetic properties in rats, suitable for preclinical research.
Conclusions:
- The developed Kir2.1 inhibitors represent an advancement over ML133.
- Compound 5s is a promising next-generation tool compound for investigating Kir2.1 biology in rodent models.
- The improved potency and PK profile of 5s will facilitate in vivo studies of Kir2.1 channel function.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
01:20Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
01:26Voltage-gated Ion Channels
10.4K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
10.4K
01:28Depolarizing Blockers: Mechanism of Action
2.7K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.7K
01:24Non-gated Ion Channels
8.0K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
8.0K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K